Pharmacogenomic considerations for immunosuppressive therapy

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.4, Iss.3, 2003-05, pp. : 309-319

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Immunosuppressive Therapy for Paediatric Transplant Patients: Pharmacokinetic Considerations

By Fernández de Gatta M.d.M.

Clinical Pharmacokinetics, Vol. 41, Iss. 2, 2002-01 ,pp. : 115-135

Adis International

Access to resources Recommend Favorite

Pharmacogenomic considerations of the paraoxonase polymorphisms

By Furlong Clement E Cole Toby B Jarvik Gail P Costa Lucio G

Pharmacogenomics, Vol. 3, Iss. 3, 2002-05 ,pp. : 341-348

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic considerations in drug delivery

By Attar Mayssa Lee Vincent HL

Pharmacogenomics, Vol. 4, Iss. 4, 2003-07 ,pp. : 443-461

Future Medicine

Access to resources Recommend Favorite

Economic and Developmental Considerations for Pharmacogenomic Technology

By Vernon John A. Johnson Scott J.

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 335-343

Adis International

Access to resources Recommend Favorite

A pharmacogenomic evaluation of migraine therapy

By Johnson Matthew P Fernandez Francesca Colson Natalie J Griffiths Lyn R

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 12, 2007-08 ,pp. : 1821-1835

Informa Healthcare

Access to resources Recommend Favorite